Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IINNW
Upturn stock ratingUpturn stock rating

Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)

Upturn stock ratingUpturn stock rating
$0.36
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: IINNW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit 25.78%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 2.12
52 Weeks Range 0.12 - 0.99
Updated Date 06/14/2025
52 Weeks Range 0.12 - 0.99
Updated Date 06/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.67

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -81.03%
Return on Equity (TTM) -219.74%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 24090830
Shares Outstanding -
Shares Floating 24090830
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Inspira Technologies Oxy B.H.N. Ltd. Warrant

stock logo

Company Overview

overview logo History and Background

Inspira Technologies Oxy B.H.N. Ltd. is focused on developing and marketing innovative respiratory support technology. The warrant represents the right to purchase shares of the company's stock under specific conditions. It aims to redefine acute respiratory care.

business area logo Core Business Areas

  • Ventilator Development: Development of advanced respiratory support systems, including the ART device.

leadership logo Leadership and Structure

The leadership team comprises individuals with experience in medical technology and business development. The organizational structure includes R&D, operations, and commercial teams.

Top Products and Market Share

overview logo Key Offerings

  • ART (Augmented Respiration Technology) System: A respiratory support system designed to minimize the need for invasive mechanical ventilation. It directly oxygenates blood. Market share data unavailable due to pre-commercialization. Competitors include traditional ventilator manufacturers such as Medtronic (MDT) and Philips (PHG).

Market Dynamics

industry overview logo Industry Overview

The respiratory care market is driven by the increasing prevalence of respiratory diseases and the need for advanced ventilation technologies.

Positioning

Inspira Technologies aims to disrupt the market with its ART system, offering a less invasive alternative to traditional mechanical ventilation. Focus is on acute respiratory failure management.

Total Addressable Market (TAM)

The global respiratory care devices market is estimated at tens of billions of dollars. Inspira is positioned to capture a segment by addressing unmet needs in early-stage respiratory support.

Upturn SWOT Analysis

Strengths

  • Innovative ART technology
  • Potential to reduce invasive ventilation
  • Focus on unmet clinical needs

Weaknesses

  • Pre-commercialization stage
  • Limited operating history
  • Reliance on regulatory approvals
  • Cash burn rate
  • Dilution via warrant excercise

Opportunities

  • Expanding respiratory care market
  • Partnerships with hospitals and healthcare providers
  • Regulatory approvals and clearances
  • Geographic expansion

Threats

  • Competition from established players
  • Technological advancements by competitors
  • Regulatory hurdles
  • Reimbursement challenges
  • Clinical trial risks

Competitors and Market Share

competitor logo Key Competitors

  • Medtronic (MDT)
  • Philips (PHG)
  • Getinge (GETI.ST)

Competitive Landscape

Inspira faces strong competition from established medical device companies with significant resources and market presence. Inspira's competitive advantage lies in its innovative ART technology, but it needs to demonstrate clinical and commercial success to compete effectively.

Growth Trajectory and Initiatives

Historical Growth: No revenue has been booked to date.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of the ART system. Analyst estimates vary widely due to the speculative nature of the company's prospects.

Recent Initiatives: Recent initiatives include advancing clinical trials for the ART system, securing regulatory approvals, and establishing partnerships for commercialization.

Summary

Inspira Technologies is a speculative investment opportunity focused on developing innovative respiratory support technology. Its potential lies in its ART system, which aims to reduce the need for invasive ventilation, but it faces significant risks due to its pre-commercialization stage, competition, and regulatory hurdles. Future success depends on successful clinical trials and commercialization, which makes this investment high-risk, high-reward.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Market research reports
  • Analyst reports

Disclaimers:

The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Inspira Technologies Oxy B.H.N. Ltd. Warrant

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-07-14
Co-Founder, CEO & Director Mr. Dagi Shahar Ben-Noon
Sector Healthcare
Industry Medical Devices
Full time employees 37
Full time employees 37

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure in Israel. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.